-
Professor Li Jin: Asian Clinical Oncology Experts Converge at FACO Conference to Jointly Promote Regional Collaboration and Advance the Level of Diagnosis and Treatment for Common Asian Cancers
The 13th International Conference of the Federation of Asian Clinical Oncology (FACO 2025) will be grandly held in Shanghai from October 24 to 25, 2025. The conference is jointly organized by the Federation of Asian Clinical Oncology (FACO), the Chinese Society of Clinical Oncology (CSCO), the Beijing CSCO Clinical Oncology Research Foundation, and the Eastern…
-
ESMO Interview | Dr. Bryan Li: From Bladder Removal to Bladder Preservation, Perioperative Immunotherapy Reshapes MIBC Treatment
Oncology Frontier- UroStream: From ASCO to ESMO, we’ve seen a surge of exciting new data in bladder cancer. The NIAGARA regimen is drawing great attention in the MIBC field. How…
-
CSCO 2025 | Professor Wei Li: PARP Inhibitors Transform Early BRCA-Mutated Breast Cancer — Precision and Combination Strategies Drive Progress
Editor’s Note: Patients carrying BRCA gene mutations face a significantly increased risk of developing breast cancer, and conventional therapies often yield suboptimal results. PARP inhibitors, by leveraging the mechanism of…
-
CSCO 2025 | Professor Guohong Song: Immunotherapy Redefines Triple-Negative Breast Cancer Through Precision and Intensified Treatment
Editor’s Note: In recent years, immunotherapy, particularly PD-1/PD-L1 inhibitors, has profoundly transformed the treatment paradigm for triple-negative breast cancer (TNBC). The KEYNOTE-522 trial demonstrated that neoadjuvant immunotherapy combined with chemotherapy…
-
The 11th Qingdao Breast Disease Conference | Professor Jian Yin: Optimizing the Management of Complications in Implant-Based Breast Reconstruction
The 11th Qingdao Breast Disease Conference and the 9th “Langya Forum” were recently held in the beautiful coastal city of Qingdao. The event brought together leading experts and emerging talents in breast oncology from across China and beyond to share cutting-edge research, discuss innovative diagnostic and therapeutic strategies, and chart the future of breast disease…
-
Oriental Insight | Professor Juliang Zhang: Insights into Adjuvant Intensified Therapy for HR+/HER2- Breast Cancer
Hormone receptor–positive, HER2-negative (HR+/HER2−) breast cancer is the most common molecular subtype of breast cancer. Although patients with this subtype generally have a favorable prognosis, its high heterogeneity means that some individuals remain at risk of disease recurrence.In recent years, adjuvant treatment strategies have been continuously refined — evolving from standard endocrine therapy to the…
-
Oriental Insight | Professors Xiaoyun Mao and Wen Xu’s Team Publishes a Comprehensive Review on Engineered Upconversion Nanoparticles for Precision Theranostics in Breast Cancer
Breast cancer remains the most common malignancy among women, with persistently high incidence and mortality rates. Its heterogeneity, drug resistance, and the toxicity associated with conventional therapies continue to challenge clinical management.In recent years, rare-earth-doped upconversion nanoparticles (UCNPs) have attracted growing attention in breast cancer research owing to their unique optical properties, tunable synthesis, and…
-
The 11th Qingdao Breast Disease Conference | Professor Xin Wang: Opportunities and Challenges in Omitting Local Therapy After Neoadjuvant Treatment
Editor’s Note: With the expanding role of neoadjuvant therapy in breast cancer, pathologic complete response (pCR) has become an important indicator for evaluating treatment efficacy. Whether patients who achieve pCR…
Connecting Medical Expertise through Media